Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lepodisiran PK Study in Healthy Participants With High Lipoprotein(a)
NCT07914738Phase 1Not yet recruiting
- Sponsor
- Eli Lilly and Company
- Start
- Nov 2026
- Primary completion
- Mar 2027
01
Overview
Phase 1, open-label trial of lepodisiran in Hyperlipoproteinemia a (3 arms), sponsored by Eli Lilly and Company. Primary endpoints: Maximum Observed Plasma Concentration and Area Under the Concentration versus Time Curve. Planned start Nov 2026; status: not yet recruiting.
02
Drugs
lepodisiran
03
Conditions
Hyperlipoproteinemia a
Beyond the preview
Go deeper on NCT07914738.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07914738.